AstraZeneca reports mixed first-quarter 2025 results. The fall in pre-market is likely due to the soft sales performance of ...

But so far, so good for the TROP2-directed treatment, which is off to a "smooth market launch,” according to Daiichi CEO ...

Roche has claimed a breakthrough designation from the FDA for a cancer test that combines an antibody assay with artificial ...

Daiichi Sankyo reaffirms US manufacturing expansion, including for Enhertu, will help with Trump's proposed tariffs. $350M ...

RxDx Device is an immunohistochemistry (IHC) assay combined with a digital pathology algorithm to determine patient treatment ...

Hiroyuki Okuzawa, CEO of Japanese pharmaceutical giant Daiichi Sankyo, talks about the company's revenue driver in its latest report, and the lack of visibility from the impact of potential U.S.

New data presented at AACR supports adding pembrolizumab before and after surgery in patients with newly diagnosed locally ...

The US FDA has granted breakthrough device designation to Roche's companion diagnostic VENTANA TROP2 (EPR20043) RxDx Device.

Daiichi Sankyo’s optimism is driven by the strong performance of Enhertu, with related revenue soaring by 45% YoY to ¥651 billion, accounting for the majority of the company’s overall revenue increase ...

AstraZeneca (AZ) and Daiichi Sankyo have shared positive results from a late-stage study of their antibody drug conjugate ...

Daiichi Sankyo seeks Japanese approval for Enhertu to treat patients with HER2 positive metastatic solid tumours: Tokyo Friday, April 25, 2025, 09:00 Hrs [IST] Daiichi Sankyo has ...